健麾信息收购博科国信38%股权，募投项目延期至2027年

Company Acquisition - The company has completed the acquisition of 38% equity in Boke Guoxin, increasing its shareholding from 32% to 70%, thus making it a subsidiary included in the consolidated financial statements [1][5] - The acquisition is based on Boke Guoxin's projected net profit of 14.33 million in 2025, priced at a P/E ratio of 13.54, with performance commitment clauses set for 2026 to 2028 [1][5] Project Progress - The completion date for the pharmacy automation upgrade R&D project and the automation equipment deployment project has been postponed to February 2027 [2][6] - As of December 31, 2025, the investment progress for the two projects stands at 33.56% and 26.84% respectively, with the delay aimed at aligning with market demand and avoiding idle capacity risks [2][6] Company Status - On February 5, 2026, the company held a board meeting to review and approve the postponement of fundraising projects and other related proposals, further clarifying the adjustments [3][7]